forxiga dapagliflozina

Forxiga, known generically as dapagliflozin, is a medication used to treat type 2 diabetes. It is part of a class of drugs known as SGLT2 inhibitors, which work by helping the kidneys remove glucose from the bloodstream. The product is manufactured by AstraZeneca, a leading global biopharmaceutical company headquartered in the United Kingdom. Forxiga is produced in multiple countries to meet global demand, ensuring availability for patients in various regions. AstraZeneca has a strong commitment to research and development, focusing on innovative treatments for chronic diseases.